A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer (ODENZA)

Gustave Roussy

Status and phase

Completed

Phase 2

Conditions

Metastatic Castrate-resistant Prostate (CRPC) Cancer

Treatments

Drug: ODM-201

Drug: Enzalutamide

Study type

Interventional

Funder types

Other

Identifiers

NCT03314324

2017-001606-14

2017/2555 (Other Identifier)

Details and patient eligibility

About

To assess patient preference between ODM-201 and enzalutamide by patient preference questionnaire

Enrollment

250 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male patients older than 18 years
Histologically confirmed adenocarcinoma of the prostate
Evidence of metastatic disease (imaging can include bon scan, CT scan, PET choline, PET PSMA and MRI)
Continued androgen deprivation therapy (ADT) either with LHRH agonists/antagonists or bilateral orchiectomy
Serum testosterone <0.50 ng/ml (1.7 nmol/L)
Progressive disease (PSA progression or radiological progression or clinical progression) as per PCWG3 criteria
ECOG 0-1 (2 is accepted if the impairment is not due to prostate cancer)
Asymptomatic or mildly symptomatic prostate cancer as measured on the Brief Pain Inventory Short Form question 3 (i.e. worst pain in the last 24 hours <4 on a Visual Analog Scale)
Information imparted to the patient and the informed consent form signed by the patient or his legal representative
Ability to comply with the protocol procedures
Patient affiliated to a social security system or beneficiary of the same
Sexually active male subjects unless surgically sterile, must agree to use condoms as an effective barrier method and refrain from sperm donation, and/or their female partners of reproductive potential to use a method of effective birth control, during the study treatment and for 3 months after the end of the treatment
adequate organ or bone marrow function as evidenced by:
Hemoglobin ≥ 9 g/dL
Absolute neutrophil count ≥ 1.5 x 109/L,
Platelet count ≥ 100 x 109/L, (subject must not have received any growth factor within 4 weeks or blood transfusion within 7 days of the hematology laboratory sample obtained at screening)
AST/SGOT and/or ALT/SGPT ≤1.5 x ULN;
Total bilirubin ≤ 1.5 x ULN, (except subjects with a diagnosis of Gilbert's disease),
Serum creatinine ≤ 2 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to the CKDEPI formula and patients with creatinine clearance <60 mL/min should be excluded.

Exclusion criteria

Prior treatment with abiraterone, enzalutamide, ODM-201, ARN- 509 or any other next-generation AR axis-targeting drug
Prior treatment with a taxane for CRPC (prior treatment with a taxane for castration-sensitive or castration-naïve prostate cancer is allowed)
Prior treatment with radium-223
Patients receiving an investigational drug within 4 weeks prior to enrolment (approved drugs with a long history of use such as aspirin, statins, heparins, or metformin, even used in an experimental setting are accepted)
Treatment with radiotherapy (external beam radiation therapy [EBRT], brachytherapy, or radiopharmaceuticals) within 2 weeks before randomization
Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs
Acute toxicities of prior treatments and procedures not resolved to grade <=1 or baseline before randomisation.
Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure (New York Heart Association (NYHA) Class III or IV)
Uncontrolled hypertension as indicated by a resting systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥100 mmHg despite optimal medical management
Had a prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e., pTis, pTa, and pT1) is allowed, as well as any other cancer for which treatment has been completed ≥5 years before randomization and from which the subject has been disease-free
A gastrointestinal disorder or procedure which is expected to interfere significantly with absorption of study treatment
An active viral hepatitis, active human immunodeficiency infection(HIV), or chronic liver disease with a need for treatment.
Any other serious or unstable illness or infection, or medical, social, or psychological condition, that could jeopardize the safety of the subject and/or his compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results
Inability to swallow oral medications